Table 1 Patient baseline demographics
Patient characteristic | huKS-IL2 dosing cohort, mg/m2 | Total (N = 27) | ||||
|---|---|---|---|---|---|---|
0.5 | 1.0 | 2.0 | 3.0 | 4.0 | ||
(n = 3) | (n = 4) | (n = 7) | (n = 6) | (n = 7) | ||
Age, years | ||||||
Median | 47 | 55 | 59 | 57 | 63 | 58 |
Range | 47–58 | 46–69 | 46–68 | 49–61 | 53–67 | 46–69 |
Sex, n (%) | ||||||
Men | 0 | 1 (25) | 4 (57) | 1 (17) | 4 (57) | 10 (37) |
Women | 3 (100) | 3 (75) | 3 (43) | 5 (83) | 3 (43) | 17 (63) |
Tumor type, n (%) | ||||||
Ovarian carcinoma | 3 (100) | 2 (50) | 3 (43) | 4 (67) | 3 (43) | 15 (56) |
Lung carcinoma | 0 | 0 | 0 | 2 (33) | 2 (29) | 4 (15) |
Colon | 0 | 2 (50) | 1 (14) | 0 | 0 | 3 (11) |
Prostate | 0 | 0 | 1 (14) | 0 | 1 (14) | 2 (7) |
Othera | 0 | 0 | 2 (29) | 0 | 1 (14) | 3 (11) |
Tumor stage, n (%) | ||||||
I | 0 | 0 | 1 (14) | 0 | 1 (14) | 2 (7) |
II | 0 | 1 (25) | 0 | 0 | 0 | 1 (4) |
III | 3 (100) | 3 (75) | 1 (14) | 4 (67) | 2 (29) | 13 (48) |
IV | 0 | 0 | 5 (71) | 2 (33) | 4 (57) | 11 (41) |
Prior chemotherapy, n (%) | 3 (100) | 4 (100) | 6 (86) | 6 (86) | 6 (86) | 25 (93) |
Prior radiotherapy, n (%) | 0 | 2 (50) | 3 (43) | 3 (43) | 3 (43) | 10 (37) |